SARASOTA, Fla., May 22, 2025 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the TD Cowen 53rd Annual Technology, Media & Telecom Conference on Thursday, May 29, 2025 at 9:05 AM (Eastern Time) in New York, NY. A link to the webcast presentation will be available in the “Investors” section of the Company’s website at www.ropertech.com. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 1000. Roper has a proven, lo ...

BTQ and Quandela MOU: BTQ Technologies and Quandela have signed a Memorandum of Understanding (MOU) to jointly explore how photonic quantum computing can advance energy-efficient blockchain validation through BTQ's Quantum Sampling Proof-of-Work (QSPoW) protocol. Future Proofing Bitcoin: QSPoW is a Bitcoin-inspired quantum-secure and energy-efficient alternative to traditional PoW mining, aimed at preserving the integrity of the world's largest digital asset in the face of advancing quantum threats. Quantu ...

Core Insights - The 10th Nanjing University of the Arts 520 Graduation Exhibition Carnival commenced on May 20, 2025, themed "Embracing AI, Digital Intelligence Empowers," featuring over 90 art exhibitions and performances until late June, showcasing the evolution of art education in the digital intelligence era [1][4]. Group 1: Event Highlights - The opening ceremony featured digital representations of historical figures Mr. Cai Yuanpei and Mr. Liu Haisu, emphasizing the legacy of modern education and art in China [2]. - Notable events include the "Digital Intelligence · Chinese Attire" fashion design showcase, the Bubble Music Festival Jazz Season, and a collaborative Chinese opera performance by students from China and Canada, highlighting multicultural artistic collaboration [4]. Group 2: Institutional Vision - Nanjing University of the Arts has focused on a vision of symbiosis between the university and the city, creating a cultural emblem that enhances the artistic landscape of Nanjing and Jiangsu over the past decade [5].

Core Insights - Biomerica, Inc. announced real-world results demonstrating the effectiveness of its inFoods IBS product, which includes a new real-time patient feedback system to enhance symptom tracking and improve patient outcomes [1][2] Group 1: Product Effectiveness - The initial analysis from over 360 patients showed an average reduction of 48.5% in gastrointestinal pain and 49.8% in bloating over an 8-week period [6][7] - The real-world outcomes align with and in some cases exceed results from prior randomized clinical trials conducted at leading U.S. medical centers [1] Group 2: Real-Time Feedback System - Biomerica's HIPAA-compliant platform provides physicians with visibility into patient-reported outcomes, allowing for data-informed decisions and adjustments to treatment plans [2] - The real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomes [6] Group 3: Market Need and Impact - IBS affects an estimated 10% to 15% of adults in the U.S., leading to decreased quality of life and reliance on medications with adverse side effects [4] - The inFoods IBS product offers a novel diagnostic-guided solution that identifies individual food triggers, enabling targeted dietary changes without pharmaceuticals [4][5] Group 4: Clinical Validation - Peer-reviewed results published in Gastroenterology indicated that patients on an inFoods IBS-guided diet experienced significantly more abdominal pain relief compared to those on a placebo diet (59.6% vs. 42.1%, p-value=0.02) [3]

Core Insights - Windtree Therapeutics is advancing its istaroxime cardiogenic shock program with the SEISMiC C Study, targeting interim analysis results for July 2025 [1][2][3] - Istaroxime is a first-in-class dual-mechanism therapy aimed at improving cardiac function in patients with cardiogenic shock [4] Company Overview - Windtree Therapeutics focuses on developing innovative therapies for critical conditions and aims to become a revenue-generating company [5] - The company's product portfolio includes istaroxime, which is in Phase 2 trials for acute heart failure and cardiogenic shock, as well as preclinical candidates for heart failure and oncology applications [5] Study Details - The SEISMiC C Study is a global, placebo-controlled, double-blinded trial assessing the efficacy of istaroxime in addition to standard care [2] - The primary endpoint is the systolic blood pressure profile over the first six hours, with additional measurements including cardiac function and treatment failure rates [2] Clinical Significance - Interim data from the SEISMiC C Study will provide insights into istaroxime's physiological impact and safety profile in more severely ill patients [3] - Previous Phase 2 studies have shown that istaroxime can significantly improve cardiac function and blood pressure without increasing heart rate or causing significant rhythm disturbances [4]

Core Insights - Northstrive Biosciences Inc. has completed a Phase I strategic research and literature synthesis for its first-in-class oral myostatin-engineered probiotic, EL-22, aimed at addressing muscle-wasting conditions [1][7] - The analysis, conducted with Yuva Biosciences, provided insights into EL-22's mechanism of action and its potential to meet critical needs in muscle-wasting conditions such as GLP-1-associated atrophy and age-related sarcopenia [1][7] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on developing innovative aesthetic medicines [4] - The lead asset, EL-22, utilizes a myostatin-engineered probiotic approach to help preserve muscle during weight loss treatments, particularly with GLP-1 receptor agonists [4] Product Highlights - EL-22 employs a myostatin-engineered probiotic strategy to combat obesity-related muscle loss during weight loss treatments, offering a patient-friendly oral delivery method [2][4] - The product is designed to induce an immune response against myostatin, a key regulator of muscle growth, using genetically engineered Lactobacillus casei [2] Research Findings - The report highlights significant effects of EL-22 in mdx mice, including improvements in antibody production, serum creatine kinase levels, body weight, motor function, and muscle histology [7] - EL-22's unique oral vaccine approach distinguishes it from traditional systemic antibody or gene therapy methods, aiming to stimulate both mucosal and systemic immunity against myostatin [7] Market Positioning - With the rise of GLP-1 receptor agonists in obesity and diabetes treatment, EL-22 is strategically positioned to address the associated muscle loss concerns [7] - Northstrive plans to initiate a Phase 2 proof-of-concept trial targeting GLP-1 users and engage in regulatory discussions to advance EL-22 towards an IND filing in the U.S. [7]

Core Insights - Predictive Oncology Inc. is leveraging over 150,000 live cell tumor samples and drug response data to enhance drug discovery and biomarker identification using AI and machine learning [1][12] - Regeneron Pharmaceuticals' acquisition of 23andMe for $256 million signifies a strategic shift towards data-driven drug discovery, emphasizing the value of genomic databases in therapeutic development [2][5] - 23andMe's extensive genomic dataset provides insights into disease progression and treatment efficacy, making it a valuable asset for precision drug development [3][4] Company Developments - Predictive Oncology has achieved a milestone in AI-enabled cancer drug discovery by developing predictive tumor response models for 21 previously untested molecules targeting common cancer types [7][8] - The company's AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to a specific drug compound, facilitating informed drug selection for testing [11][12] - The integration of AI and machine learning with real-world drug response data allows Predictive Oncology to expedite early-stage drug discovery and reduce risks in drug development [9][10] Industry Trends - The acquisition of 23andMe by Regeneron reflects a broader trend in the biopharma industry towards the convergence of AI, real-world data, and predictive analytics to enhance therapeutic outcomes [5][10] - The life sciences sector is undergoing a transformation where the integration of genomics and machine learning is becoming a foundational element in precision medicine [10]

Group 1 - Ocean Power Technologies, Inc. has successfully completed its first WAM-V 22 sea trials for a significant customer operating in Sub Saharan Africa, conducted at its newly permitted test site in Southern New Jersey [1][2] - The completion of these sea trials allows the company to conduct year-round testing on both the East and West Coasts, facilitating quicker product delivery and reducing the time from booking to revenue recognition [2] - Ocean Power Technologies specializes in intelligent maritime solutions, including AI-capable systems for maritime domain awareness, PowerBuoy platforms for clean energy, and WAM-V unmanned surface vehicles [3]

Core Viewpoint - Nvidia has experienced remarkable growth of 1,321% over five years, establishing itself as a leader in the AI sector, but Qualcomm is emerging as a potential rival due to its focus on Edge AI and cost-effective chip solutions [1][2][3]. Group 1: Nvidia's Market Position - Nvidia continues to dominate the AI and semiconductor sectors despite a -13.04% year-to-date performance dip, benefiting from data centers and enterprise software solutions [2]. - The company has a market cap that surpasses most tech giants, solidifying its position in the AI race [1]. Group 2: Qualcomm's Strategic Shift - Qualcomm is reinventing itself by focusing on Edge AI, aiming to bring artificial intelligence closer to users through smartphones, PCs, and electric vehicles [3]. - The company's expertise in low-power, high-efficiency chips positions it well for the anticipated shift towards more hands-on AI systems [3]. Group 3: Growth Predictions for Qualcomm - Predictions indicate Qualcomm stock could see a maximum increase of +48.70% over the next 12 months, with an average projected growth of +13.23% [4]. - Recent advancements by DeepSeek in developing affordable AI models could enhance Qualcomm's market position, as the company reported a 17% year-over-year revenue growth and a 21% earnings per share increase in Q2 FY2025 [7]. Group 4: Electric Vehicle Market Potential - The electric vehicle industry is projected to grow at a steady annual rate of 6.01% by 2029, reaching a market volume of approximately US$990.4 billion [8]. - Lower-cost AI solutions are expected to be favored by automakers for scaling smart car features, aligning with Qualcomm's focus on cost-effective chip solutions [9]. Group 5: Partnerships and Future Outlook - Qualcomm has previously collaborated with major automakers like BMW and Mercedes-Benz, indicating potential for future high-profile partnerships in the automotive sector [9]. - With a strong foothold in the automotive industry and a focus on affordable chip solutions, Qualcomm may capitalize on the next wave of AI adoption, similar to Nvidia's trajectory [10].

Core Insights - ASML has developed the High NA machine, the world's most advanced and expensive chipmaking machine, with a cost exceeding $400 million, which is set to transform microchip production [1][4][12] - The first commercial installation of High NA occurred at Intel's Oregon chip fabrication plant in 2024, with only five machines shipped to date [3][4] - High NA is expected to be utilized by all ASML's EUV customers, including major chipmakers like TSMC, Samsung, and Micron, enhancing chip production efficiency and yield [4][21] Technology and Development - High NA machines are larger than a double-decker bus and consist of four modules manufactured in different locations, requiring significant logistics for delivery [2] - The technology behind High NA allows for higher resolution projections of chip designs, reducing the need for multiple patterning and improving yield [7][13] - ASML's High NA machines have shown significant improvements over previous EUV machines, with Intel reporting a 100% increase in reliability and Samsung noting a 60% reduction in cycle time [6][7] Market Position and Strategy - ASML holds a dominant position in the EUV lithography market, being the exclusive manufacturer of these machines, which are essential for producing advanced microchips [4][5] - The company sold 44 EUV machines in 2024, with a starting price of $220 million, while its older DUV machines accounted for 60% of its business [16][17] - ASML's sales to China peaked at 49% of its business in Q2 2024, but are expected to normalize to 20%-25% in 2025 due to U.S. export controls on EUV technology [17][18] Future Outlook - ASML plans to ship at least five more High NA systems in the current year and aims to ramp up production capacity to 20 machines in the coming years [24] - The company is also developing the next generation of machines, Hyper NA, expected to be needed between 2032 and 2035, with draft optical designs already in progress [23][24] - ASML is establishing a training center in Arizona to train 1,200 individuals annually on EUV and DUV technologies, addressing the growing demand for skilled labor in the semiconductor industry [23]